{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:49:34Z","timestamp":1794660574358,"version":"4.9.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>The concept of difficult-to-treat (D2T) disease is increasingly recognized across immune-mediated inflammatory diseases, and was recently introduced in spondyloarthritis (SpA). Several terms, including difficult-to-manage (D2M), complex-to-manage (C2M), and treatment-refractory (TR) describe disease states characterized by persistent symptoms and inadequate response to targeted therapies. This review aims to clarify the emerging constructs of D2M and TR disease in axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), and their implications for emerging research in this area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Recent initiatives from ASAS, EULAR, and GRAPPA have proposed definitions to frame D2T clinical scenarios  in axSpA and PsA. These converge on distinguishing treatment-refractory disease, characterized by persistent objective inflammation despite multiple targeted therapies, from broader D2M\/C2M states driven by multifactorial contributors including non-inflammatory factors. Emerging data suggest that clinical and biological heterogeneity across disease domains may contribute to these phenotypes. Challenging phenotypic presentations often display overlapping features between axSpA and PsA, supporting the concept of a continuum across the SpA spectrum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Distinguishing TR disease from broader D2M\/C2M states is essential for avoiding inappropriate treatment escalation, and supporting personalized multidisciplinary care. Further research is needed to validate these definitions, determine contributing factors and their prevalence, and clarify the molecular mechanisms underlying treatment refractory disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001173","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:00:17Z","timestamp":1781247617000},"page":"343-348","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?"],"prefix":"10.1097","volume":"38","author":[{"given":"Olivier","family":"Fakih","sequence":"first","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"Universit\u00e9 Marie et Louis Pasteur, Service de rhumatologie, CHU de Besan\u00e7on, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Rose","family":"Harrison","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"R1-20260730","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ard.2025.01.035","article-title":"The Assessment of SpondyloArthritis International Society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis","volume":"84","author":"Poddubnyy","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R2-20260730","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ard.2025.10.002","article-title":"EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis","volume":"85","author":"Marzo-Ortega","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R3-20260730","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41584-025-01329-3","article-title":"Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative","volume":"22","author":"Proft","year":"2026","journal-title":"Nat Rev Rheumatol"},{"key":"R4-20260730","doi-asserted-by":"crossref","first-page":"e003809","DOI":"10.1136\/rmdopen-2023-003809","article-title":"Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project","volume":"10","author":"Singla","year":"2024","journal-title":"RMD Open"},{"key":"R5-20260730","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R6-20260730","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R7-20260730","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of psoriatic arthritis","volume":"47","author":"Merola","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R8-20260730","doi-asserted-by":"crossref","first-page":"152737","DOI":"10.1016\/j.semarthrit.2025.152737","article-title":"Biologic switching in psoriatic arthritis: Insights from real-world data and key risk factors","volume":"73","author":"Haddad","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"R9-20260730","doi-asserted-by":"crossref","first-page":"rkae074","DOI":"10.1093\/rap\/rkae074","article-title":"Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals","volume":"8","author":"Ribeiro","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"R10-20260730","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1093\/rheumatology\/keaf207","article-title":"Deciphering difficult-to-treat psoriatic arthritis: insights from an international survey of patients with psoriatic arthritis","volume":"64","author":"Ribeiro","year":"2025","journal-title":"Rheumatology"},{"key":"R11-20260730","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard-2023-225087","article-title":"Time to address the challenge of difficult to treat psoriatic arthritis: results from an international survey","volume":"83","author":"Marzo-Ortega","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R12-20260730","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R13-20260730","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","article-title":"Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis","volume":"17","author":"Buch","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"R14-20260730","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R15-20260730","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41584-023-01038-9","article-title":"Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis","volume":"19","author":"McGonagle","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"R16-20260730","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/rheumatology\/keaf120","article-title":"Exploring difficult-to-manage axial spondyloarthritis: results from a Dutch clinical practice registry","volume":"64","author":"Smits","year":"2025","journal-title":"Rheumatology"},{"key":"R17-20260730","doi-asserted-by":"crossref","first-page":"keaf641","DOI":"10.1093\/rheumatology\/keaf641","article-title":"Frequency of difficult-to-manage and treatment-refractory axial SpA: insights from the German RABBIT-SpA register using recent ASAS definitions","volume":"65","author":"Proft","year":"2026","journal-title":"Rheumatology"},{"key":"R18-20260730","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ard.2025.05.509","article-title":"POS0121 difficult-to-manage patients with axial spondyloarthritis: insights from the Greek AxSpA Registry","volume":"84","author":"Kougkas","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R19-20260730","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/rheumatology\/keae263","article-title":"Identification and characteristics of patients with potential difficult-to-treat psoriatic arthritis: exploratory analyses of the Greek PsA registry","volume":"63","author":"Vassilakis","year":"2024","journal-title":"Rheumatology"},{"key":"R20-20260730","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/rheumatology\/key199","article-title":"Combined inhibition of tumour necrosis factor-alpha and interleukin-12\/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways?","volume":"57","author":"De Marco","year":"2018","journal-title":"Rheumatology"},{"key":"R21-20260730","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1136\/annrheumdis-2016-209275","article-title":"Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis","volume":"75","author":"Merashli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R22-20260730","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1093\/rheumatology\/keae005","article-title":"Exploring the unifying concept of spondyloarthritis: a latent class analysis of the REGISPONSER registry","volume":"63","author":"Michelena","year":"2024","journal-title":"Rheumatology"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:00:28Z","timestamp":1785394828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001173","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}